[Federal Register Volume 60, Number 228 (Tuesday, November 28, 1995)]
[Notices]
[Page 58628]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-28916]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has made final findings of scientific misconduct in the following 
case:
    Tetsuya Matsuguchi, M.D., Ph.D., Dana-Farber Cancer Institute: On 
November 3, 1995, ORI found that Tetsuya Matsuguchi, M.D., Ph.D., 
formerly a Harvard Medical School Research Fellow at the Dana-Farber 
Cancer Institute, committed scientific misconduct by intentionally 
falsifying data by artificially darkening one band each on two 
autoradiographs in figures that he had prepared for a presentation at 
an intramural research seminar and by altering three bands on the print 
of an immunoblot included in Figure 2A of a paper published in the EMBO 
Journal. This research was supported by a Public Health Service grant.
    Dr. Matsuguchi has entered into a Voluntary Exclusion Agreement 
with ORI in which he has accepted ORI's finding and has agreed to 
exclude himself voluntarily, for the three (3) year period beginning 
November 3, 1995:
    (1) From any contracting or subcontracting with any agency of the 
United States Government and from eligibility for, or involvement in, 
Federal nonprocurement transactions (e.g., grants and cooperative 
agreements), of the United States Government, as defined in 45 C.F.R. 
Part 76 and 48 C.F.R. Subparts 9.4 and 309.4 (Debarment Regulations); 
and
    (2) From serving in any advisory capacity to PHS, including but not 
limited to service on any PHS advisory committee, board, and/or peer 
review committee, or as a consultant.
    The above voluntary exclusion, however, shall not apply to Dr. 
Matsuguchi's future training or practice of clinical medicine whether 
as a medical student, resident, fellow, or licensed practitioner unless 
that practice involves research or research training.
    Dr. Matsuguchi has agreed to submit a letter to the EMBO Journal 
requesting correction of the article entitled ``Tyrosine 
phosphorylation of p85Vav in myeloid cells is regulated by GM-CSF, 
IL-3, and Steel factor and is constitutively increased by p210BCR/
ABL'' (EMBO Journal 14:257-265, 1995) by retracting Figure 2A, because 
Dr. Matsuguchi enhanced the Vav bands in lanes 2, 3, and 4 without the 
knowledge of the other authors, and by substituting the correct Figure 
2A.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research 
Investigations, Office of Research Integrity, 5515 Security Lane, Suite 
700, Rockville, MD 20852.
Lyle W. Bivens,
Director, Office of Research Integrity.
[FR Doc. 95-28916 Filed 11-27-95; 8:45 am]
BILLING CODE 4160-17-P